Patents by Inventor Simon William Keen

Simon William Keen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
    Patent number: 9587024
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 7, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor I (IGF-1)
    Publication number: 20150259422
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 17, 2015
    Inventors: David CLEMMONS, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
    Patent number: 9073996
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?V?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: July 7, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Cancer treatment using humanized antibodies that bind to EphB4
    Patent number: 8975377
    Abstract: In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: March 10, 2015
    Assignee: Vasgene Therapeutics, Inc
    Inventors: Parkash Gill, Valery Krasnoperov, Simon William Keen, Timothy David Jones, Francis Joseph Carr
  • MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR 1 (IGF-1)
    Publication number: 20140072568
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?V?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 13, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Cancer treatment using humanized antibodies that bind to EphB4
    Publication number: 20090196880
    Abstract: In certain embodiments, this application provides humanized antibodies that bind to the EphB4 protein as well as uses of the antibodies for therapeutic purposes.
    Type: Application
    Filed: August 11, 2008
    Publication date: August 6, 2009
    Applicant: Vasgene Therapeutics, Inc.
    Inventors: Parkash Gill, Valery Krasnoperov, Simon William Keen, Timothy David Jones, Francis Joseph Carr